IGM Biosciences (IGMS) PT Lowered to $16 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IGMS Hot Sheet
Price: $1.27 --0%
Rating Summary:
3 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
3 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
Wedbush analyst Robert Driscoll lowered the price target on IGM Biosciences (NASDAQ: IGMS) to $16.00 (from $19.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Pfizer (PFE) PT Raised to $40 at Argus
- Datadog (DDOG) PT Lowered to $230 at Jefferies
- Stanley Black & Decker (SWK) PT Raised to $135 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
